Balancing ethics with economy in outsourced clinical trials
Concerns are frequently raised in the pharmaceutical industry over the danger that when clinical trials are outsourced to contact research organisations (CROs), ethical protections might take a backseat to quicker and cheaper new product development.
- (1888PressRelease) April 14, 2011 - Concerns are frequently raised in the pharmaceutical industry over the danger that when clinical trials are outsourced to contact research organisations (CROs), ethical protections might take a backseat to quicker and cheaper new product development. Outsourcing of trials to CROs and offshoring to developing economies, particularly in a sector fixated on driving productivity and cost reductions, emphasises the need for independent monitoring and compulsory registration.
This argument was put forward in a recent report by Dutch non-profit group SOMO (Centre for Research on Multinational Corporations), which was dismissed by some in the industry for being full of criticism and concern, but lacking in firm evidence of harm caused by lax regulatory oversight or insufficient exercise of sponsor responsibilities.
To access this complimentary article in full please click here: http://bit.ly/h9iynr
Clinical Data Standardisation & Management 2011 will be hosted from 6th - 8th June 2011 in London, UK. For more details, please visit the website: www.clinicaldataevent.com, call freephone: 0800 652 2363 or email: enquire ( @ ) iqpc dot co.uk.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam